MeMed For Profit
The immune system is built to communicate. Our mission is to listen. We apply machine learning to translate the complex signaling of the immune system into simple, actionable diagnostic insights. MeMed�s machine learning-based diagnostics address key clinical and medical challenges in infectious diseases and inflammatory disorders. MeMed BV Bacterial and viral infections are often clinically indistinguishable
Investors
Connections from
Technology:
Biomarker panels
Headquarters:
Tirat Carmel, Hefa, Israel
Funding Status:
Late Stage Venture
Investment Stage:
N/A
Founded Date:
2009
Number Of Exists:
N/A
Estimated Revenue:
$26 Million
Employee Number:
101-250
Industry:
Biomarkers of Longevity
Investor Type:
N/A